Default company panoramic image

Innoheart Pte Ltd

Asia’s 1st & only GLP Med Device pre-clinical CRO offering high value svcs in a cost efficient, IP protected & research friendly country.

  • Stage Concept Only
  • Industry Not Set
  • Location Singapore General Hospital Outram Road Singapore
  • Currency SGD

Company Summary

Innoheart is Asia's first certified Good Laboratory Practice (GLP) medical device pre-clinical contract research organization (CRO), providing in-life pre-clinical studies to academic & research institutions, hospitals and medical device companies for evaluating complex medical devices (eg. coronary and peripheral stents), biologics (eg. cell therapy for regenerative medicine) and medical and endovascular implants (eg. pacemakers).


  • Default avatar
    Philip Wong

    CEO & CTO, practicing interventional cardiologist with in-depth knowledge of the latest devices and has implanted 5000 plus coronary stents in humans. Has been a practicing physician for 21 years. Also involved in research on devices and has intimate knowledge on testing protocols for cardiovascular devices. Has more than 10 years experience in the pre-clinical research arena and has undertaken complex pre-clinical studies in diverse areas.

  • Default avatar
    Winston Shim

    CSO, scientist and expert in stem cell and molecular imaging and biology with more than 10 years experience in these fields. Also experienced in all forms of pre-clinical testing of cardiovascular research and devices. Runs Innoheart’s histological services and molecular imaging services, key components in any pre-clinical testing facility.